Monopar Therapeutics (MNPR) Institutional Ownership $32.06 +0.22 (+0.69%) Closing price 04:00 PM EasternExtended Trading$32.06 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Monopar Therapeutics (NASDAQ:MNPR)CurrentInstitutional OwnershipPercentage1.83%Number ofInstitutional Buyers(last 12 months)17TotalInstitutional Inflows(last 12 months)$61.60MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$1.08M Get MNPR Insider Trade Alerts Want to know when executives and insiders are buying or selling Monopar Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data MNPR Institutional Buying and Selling by Quarter Monopar Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2025 Bank of America Corp DE2,109$75K0.0%-14.9%0.034% 8/14/2025 MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.2,222$80K0.0%N/A0.036% 8/13/2025 Affinity Asset Advisors LLC67,500$2.42M0.3%+8.9%1.104% 8/13/2025 New York State Common Retirement Fund2,900$104K0.0%N/A0.047% 8/12/2025 Rhumbline Advisers5,850$209K0.0%N/A0.096% 8/12/2025 JPMorgan Chase & Co.1,921$69K0.0%+1,821.0%0.031% 8/8/2025 Police & Firemen s Retirement System of New Jersey964$34K0.0%N/A0.016% 8/8/2025 Geode Capital Management LLC96,919$3.47M0.0%+99.7%1.584% 7/31/2025 AlphaQuest LLC1,784$64K0.0%+46.8%0.029% 6/27/2025 Goldman Sachs Group Inc.18,480$673K0.0%N/A0.302% Get the Latest News and Ratings for MNPR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 5/19/2025 Jane Street Group LLC10,357$377K0.0%N/A0.169% 5/16/2025 Goldman Sachs Group Inc.18,480$673K0.0%N/A0.302% 5/16/2025 ADAR1 Capital Management LLC100,774$3.67M0.7%-22.5%1.648% 5/15/2025 OMERS ADMINISTRATION Corp9,000$328K0.0%N/A0.147% 5/14/2025 Affinity Asset Advisors LLC62,000$2.26M0.2%N/A1.014% 5/14/2025 AlphaQuest LLC1,215$44K0.0%N/A0.020% 4/23/2025 Gerber LLC5,601$204K0.2%N/A0.092% 2/17/2025 Point72 Asset Management L.P.167,892$3.69M0.0%N/A2.752% 2/17/2025 Janus Henderson Group PLC1,046,899$23.44M0.0%N/A17.162% 2/14/2025 RA Capital Management L.P.511,207$11.25M0.1%N/A8.380% 2/14/2025 Adage Capital Partners GP L.L.C.599,195$13.18M0.0%N/A9.823% 2/13/2025 ADAR1 Capital Management LLC130,037$2.86M0.6%N/A2.132% 2/12/2025 Geode Capital Management LLC38,596$849K0.0%+174.4%0.633% 2/12/2025 JPMorgan Chase & Co.2,037$45K0.0%N/A0.033% 10/31/2023 Windsor Advisory Group LLC89,974$56K0.1%N/A0.635% 8/13/2021 Geode Capital Management LLC28,761$169K0.0%+9.0%0.229% 8/13/2021 Vanguard Group Inc.97,462$574K0.0%+116.2%0.775% 5/21/2021 Citadel Advisors LLC12,479$77K0.0%N/A0.099% 5/17/2021 Royal Bank of Canada9,130$57K0.0%N/A0.073% (Data available from 1/1/2016 forward) MNPR Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of MNPR shares? During the previous two years, 19 institutional investors and hedge funds held shares of Monopar Therapeutics. The most heavily invested institutionals were Janus Henderson Group PLC ($23.44M), Adage Capital Partners GP L.L.C. ($13.18M), RA Capital Management L.P. ($11.25M), Point72 Asset Management L.P. ($3.69M), ADAR1 Capital Management LLC ($3.67M), Geode Capital Management LLC ($3.47M), and Affinity Asset Advisors LLC ($2.42M).Learn more on Monopar Therapeutics' institutional investors. What percentage of Monopar Therapeutics' stock is owned by institutional investors? 1.83% of Monopar Therapeutics' stock is owned by institutional investors. Learn more on MNPR's institutional investor holdings. Which institutional investors have been buying Monopar Therapeutics' stock? Of the 18 institutional investors that purchased Monopar Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Janus Henderson Group PLC ($1.05M), Adage Capital Partners GP L.L.C. ($599.20K), RA Capital Management L.P. ($511.21K), Point72 Asset Management L.P. ($167.89K), ADAR1 Capital Management LLC ($130.04K), Windsor Advisory Group LLC ($89.97K), and Geode Capital Management LLC ($72.91K). How much institutional buying is happening at Monopar Therapeutics? Institutional investors have bought a total of 2,675,135 shares in the last 24 months. This purchase volume represents approximately $61.60M in transactions. Which of Monopar Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Monopar Therapeutics stock in the last 24 months: ADAR1 Capital Management LLC ($29.26K), and Bank of America Corp DE ($369.00). How much institutional selling is happening at Monopar Therapeutics? Institutional investors have sold a total of 29,632 shares in the last 24 months. This volume of shares sold represents approximately $1.08M in transactions. Related Companies Mineralys Therapeutics Major Shareholders Immunome Major Shareholders atai Life Sciences Major Shareholders Urogen Pharma Major Shareholders Oculis Major Shareholders Oric Pharmaceuticals Major Shareholders Nuvation Bio Major Shareholders Sionna Therapeutics Major Shareholders Niagen Bioscience Major Shareholders Valneva Major Shareholders This page (NASDAQ:MNPR) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access